XOMA Corporation (XOMA)
$21.03
-0.74 (-3.40%)
Rating:
Recommendation:
Buy
| Symbol | XOMA |
|---|---|
| Price | $21.03 |
| Beta | 0.888 |
| Volume Avg. | 0.03M |
| Market Cap | 241.025M |
| Shares () | - |
| 52 Week Range | 15.68-32.09 |
| 1y Target Est | - |
| DCF Unlevered | XOMA DCF -> | |
|---|---|---|
| DCF Levered | XOMA LDCF -> | |
| ROE | -6.24% | Neutral |
| ROA | -5.88% | Neutral |
| Operating Margin | - | |
| Debt / Equity | 13.20% | Neutral |
| P/E | -10.46 | Strong Sell |
| P/B | 1.94 | Strong Buy |
Latest XOMA news
About
Download (Excel)XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.